CytomX Therapeutics, Inc.

Good afternoon, everyone. Thank you for standing by. Welcome to the Cytomics Therapeutics fourth quarter and full year 2021 financial results call. Please be advised that today's call is being recorded. I would now like to hand the call over to your host today, Chaoqing Cytomics' Vice President, Investor Relations and Corporate Communications. Please go ahead.

Thank you, Michelle. Good afternoon, and thank you for joining us. With me today are Dr. Sean McCarty, CITOMX's Chief Executive Officer and Chairman, Dr. Amy Peterson, President and Chief Operating Officer, and Chris Obden, Vice President, Finance and Accounting. Earlier today, we issued a press release that includes a summary of our fourth quarter and full year 2021 financial results and highlight the important progress we made during the year. We encourage everyone to read today's press release and the associated materials, which have been filed with the SEC. Additionally, the press release and recording of this call can be found under the Investors and News section of our website at sitomics.com. Please note that during today's call, we will be making forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks, including the uncertainty surrounding the COVID-19 pandemic. that are difficult to predict and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filings with SEC at SEC.gov, including our Form 10-K filed today. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise. With that, I'd like to turn the call now over to Sean.

Thanks, Chao, and good afternoon, everyone. Thanks for joining us today for an update on recent progress at Citomics. Before I begin, I'd like to note that on February 14th, we issued an 8K announcing that our Chief Financial Officer, Carlos Campoy, has begun a temporary personal leave of absence. We very much look forward to Carlos' return. In the interim, our Vice President of Finance, Chris Ogden, who joins us on the call today, has assumed the role of Principal Accounting Officer and will oversee day-to-day operations of our finance functions. I would also like to congratulate Amy on her recent promotion to President and Chief Operating Officer of Cytomics, an expanded role in which she will have responsibility for all aspects of product development as we advance towards potential registrational studies and beyond. I would like to start today's call by taking a step back to comment on our overarching corporate strategy, and to reflect on our many accomplishments over the past year, resulting from sustained and relentless execution by the Cytomix team. I'll then hand the call over to Amy to provide updates on our broad and increasingly mature therapeutic pipeline. Cytomix is a clinical stage oncology-focused biopharmaceutical company dedicated to destroying cancer differently. We are utilizing our industry-leading proprietary ProBody platform to create biologic therapeutics to make the biggest possible difference we can to the lives of people with cancer. Our ambition is to build a long-term, multi-product, commercial biopharmaceutical company. Our innovative platform is designed to enable conditional activation of therapeutic candidates within the tumor microenvironment, minimizing drug activity in healthy tissues, resulting in more selective targeting of tumor tissues. we have established conditional activation as a strategic area of current biologics research and development in the industry. We believe our innovative approach has the potential to improve cancer treatment in three ways. Firstly, allowing the pursuit of high potential targets that were previously considered undruggable due to their ubiquitous expression on normal tissues. Secondly, enhancing a potential product's therapeutic window, the balance between tolerability and anti-tumor activity, with particular focus on potent immunotherapies. And thirdly, enabling the development of new combination therapies, including immunotherapies, by improving tolerability. We are employing our platform to address some of the biggest challenges today in oncology biologics R&D. These include the validation of potential new targets for antibody drug conjugates, opening solid tumor opportunities for T-cell engaging bispecific antibodies, and increasing the therapeutic window for immune modulators such as cytokines and checkpoint inhibitors. We have utilized our multi-modality pro-body platform to build a deep clinical pipeline that now encompasses six novel product candidates, four of which are currently in multiple phase two clinical studies across nine cancer types. The breadth, depth, and range of our pipeline is unmatched in the field of conditional activation, We have treated more than 400 patients with ProBody Therapeutics, and we have probed key translational questions in the clinic to validate the performance of our platform. And we continue to add to our strong intellectual property portfolio, which now comprises over 550 issued and pending patents. Our product candidates include the conditionally activated ADCs, Pralusatumab-Ravtanzine, which targets CD166, and CX2029, which targets CD71. These Phase II clinical programs highlight our strategy of leveraging our technology to pursue high-potential, previously undruggable targets. Our pipeline also encompasses the anti-CTLA-4 probody, BMS 986249, and the probody immune checkpoint inhibitor, pacmelamab, targeting PD-L1, both of which are also in Phase II studies. These product candidates highlight our strategy of using the probody platform to improve therapeutic window for potent immunotherapies broadening the clinical utility of these important pathways. In addition to our Phase II programs, our versatile and tunable platform has continued to deliver new product candidates for advancement into the clinic. CX904 is our first conditionally activated T-cell engaging bispecific antibody, targeting EGFR on tumor cells and the CD3 receptor on T-cells. In January 2022, the IND for this program was cleared by the FDA and we're in the process of initiating a first in human phase one study in patients with advanced solid tumors. Our integrated corporate strategy has and continues to encompass the formation of major partnerships with pharmaceutical and biotechnology companies. To date, we have formed multiple strategic alliances with major multinational pharma companies, including AbbVie, Amgen, Astellas, and Bristol-Myers Squibb. These alliances not only broaden the impact of our technology platform, by increasing the number of pro-body therapeutic candidates being advanced into clinical studies, but they have also added considerable financial resources in the form of non-dilutive capital, enabling us to consistently maintain balance sheet strength over the years. Today, we have reported a 2021 year-end cash balance of $305 million, which provides funding well into 2023, without taking into account any potential cash flows from existing or new partnerships. Chris will provide you with an overview of our financials momentarily. Our successful financing of Cytomics, coupled with our prudent financial management, has allowed us to aggressively advance our pipeline to key upcoming milestones and value inflection points and to build a broad early-stage pipeline that extends beyond our six clinical-stage assets as we continue to innovate and reinforce our lead in the field of conditional activations. Let me now hand the call over to Amy to walk through our many exciting achievements in the pipeline in 2021 and also our outlook for 2022. Thank you, Sean.